{"id":597626,"date":"2026-06-04T22:18:39","date_gmt":"2026-06-04T22:18:39","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/597626\/653-million-revenue-in-2025-followed-by-q1-2026-record-of-179-million-with-momentum-continuing-in-q2-for-diversified-global-heath-leader-cosmos-health-inc-nasdaq-cosm.html"},"modified":"2026-06-04T22:18:39","modified_gmt":"2026-06-04T22:18:39","slug":"653-million-revenue-in-2025-followed-by-q1-2026-record-of-179-million-with-momentum-continuing-in-q2-for-diversified-global-heath-leader-cosmos-health-inc-nasdaq-cosm","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/597626\/653-million-revenue-in-2025-followed-by-q1-2026-record-of-179-million-with-momentum-continuing-in-q2-for-diversified-global-heath-leader-cosmos-health-inc-nasdaq-cosm.html","title":{"rendered":"$65.3 Million Revenue in 2025 Followed by Q1 2026 Record of $17.9 Million with Momentum Continuing in Q2 for Diversified Global Heath Leader Cosmos Health Inc. (Nasdaq: COSM)"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.globalnewslines.com\/uploads\/2026\/06\/1780462869.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"$65.3 Million Revenue in 2025 Followed by Q1 2026 Record of $17.9 Million with Momentum Continuing in Q2 for Diversified Global Heath Leader Cosmos Health Inc. (Nasdaq: COSM)\" src=\"https:\/\/www.globalnewslines.com\/uploads\/2026\/06\/1780462869.jpg\" alt=\"$65.3 Million Revenue in 2025 Followed by Q1 2026 Record of $17.9 Million with Momentum Continuing in Q2 for Diversified Global Heath Leader Cosmos Health Inc. (Nasdaq: COSM)\" width=\"225\" height=\"133\" \/><\/a><\/div>\n<div style=\"clear:both\"><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">Guidance Targeting $200M Revenue, Adjusted EBITDA to $44.2 Million and Stockholders&#8217; Equity Growing 402% to $92.3 Million<\/div>\n<ul style=\"text-align: justify\">\n<li><em>Portfolio of Proprietary Pharmaceutical and Nutraceutical Brands, Including Sky Premium Life&reg;, Mediterranation&reg;, bio-bebe&reg;, C-Sept&reg; and C-Scrub&reg;.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Manufacturing Pharmaceuticals, Food Supplements, Cosmetics, Biocides and Medical Devices Within the European Union.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Markets to Retail Pharmacies and Wholesale Distributors Through Subsidiaries in Greece and the UK.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>R&amp;D Partnerships for Major Health Disorders Enhanced by AI Drug Repurposing via Novel Patented Nutraceuticals, Root Extracts, Proprietary Complex Generics and OTC Products.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Entered the Telehealth Space Through the Acquisition of ZipDoctor, Inc., Based in Texas with a Global Distribution Platform.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Total Liabilities Decreased by $4.5 Million, or 9.6%, Quarter-Over-Quarter, While Stockholders&#8217; Equity Increased 7.6%.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>R&amp;D Division in Discussions with the European Investment Bank for Financing of up to &euro;25 million.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>4,874,126 Series B Warrants Expired Unexercised, Eliminating ~38% of Total Warrant Overhang with Zero Shareholder Dilution.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Wholly Owned Real Estate Facilities Independently Valued at Approximately $15 Million &mdash; Exceeding Current Market Capitalization.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Guidance Projects Stockholders&#8217; Equity of $92.3 Million by 2029, Driven by a Growing Cash Position of $62.9 Million from Internally Generated Cash Flow.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Entering $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Revenue Increasing 207% at a 32% CAGR: From $65.3 Million in 2025 to $200.6 Million by 2029, Driven by Strong Growth Across All Core Segments.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Gross Profit Growing 801% to $71.2M: Margins Expanding From 12.1% to 35.5% Driven by a Structural Shift Toward High-Margin Proprietary Segments.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Net Income Improving by $50.1M: Transition to Profitability in 2027; Net Income of $31.0 Million by 2029.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Self-Funding Growth Model: Operating Cash Flow Turning Positive in 2027 at $11.9 Million, More Than Doubling to $24.0 Million by 2029.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Balance Sheet Transformation: Cash up 18-Fold to $62.9 Million; All Convertible Notes Repaid; Cash Anticipated to Exceed Total Debt Levels by 2027.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Shareholder Value: Stockholders&#8217; Equity up 402% to $92.3 Million and Per-Share Value Creation with EPS of $0.73 by 2029.<\/em><\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li><em>Clear Growth Drivers: High-Margin Proprietary Products, Distribution and Manufacturing Expansion, Global Partnerships, R&amp;D Advancement, AI-Driven Efficiencies and Disciplined Capital.<\/em><\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong><br \/>Cosmos Health, Inc. (Nasdaq: COSM) $COSM<\/strong> is a diversified, vertically integrated global healthcare group. <strong>COSM<\/strong> owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life&reg;, Mediterranation&reg;, bio-bebe&reg;, C-Sept&reg; and C-Scrub&reg;. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), <strong>COSM<\/strong> manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union.<\/p>\n<p style=\"text-align: justify\"><img decoding=\"async\" src=\"https:\/\/www.globalnewslines.com\/uploads\/2026\/06\/f78c056afba58b76efe6aff4b009ba9e.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify\"><strong>COSM<\/strong> also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, <strong>COSM<\/strong> has established R&amp;D partnerships targeting major health disorders such as obesity, diabetes and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&amp;D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products.<\/p>\n<p style=\"text-align: justify\"><strong>COSM<\/strong> has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, <strong>COSM<\/strong> is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK.<\/p>\n<p style=\"text-align: justify\"><strong>European Investment Bank Financing Discussions for up to &euro;25M, Eliminating 38% of Warrants with No Dilution, Reaffirming Business Growth Trajectory<\/strong><\/p>\n<p style=\"text-align: justify\">On June 2nd <strong>COSM<\/strong> provided an update on its balance sheet and noted no known business reason for the recent decline in its share price. The <strong>COSM <\/strong>balance sheet is trending positively across multiple key metrics, as reported in the Company&#8217;s Q1 2026 results:<\/p>\n<p style=\"text-align: justify\">Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, driven by a substantial reduction in convertible note and credit facility balances<\/p>\n<p style=\"text-align: justify\">Stockholders&#8217; equity increased by $1.4 million, or 7.6%, quarter-over-quarter<\/p>\n<p style=\"text-align: justify\">Liabilities-to-assets ratio improved by 370 basis points to 68.2% from 71.9% at year-end 2025<\/p>\n<p style=\"text-align: justify\">Liquid assets of $4.3 million comprising cash of $2.2 million and digital assets and marketable securities of $2.1 million<\/p>\n<p style=\"text-align: justify\">Beyond the quarterly metrics, The <strong>COSM<\/strong> balance sheet is underpinned by a diversified asset base spanning GMP-certified manufacturing facilities, a robotic logistics warehouse, pharmaceutical distribution infrastructure, proprietary intellectual property, digital assets, and a growing U.S. commercial platform.<\/p>\n<p style=\"text-align: justify\"><strong>COSM<\/strong> is in discussions with the European Investment Bank (EIB) for financing of up to &euro;25 million, reflecting up to 50% of its broader &euro;50 million R&amp;D initiative. If successfully concluded, this financing would represent a significant milestone for the <strong>COSM<\/strong> R&amp;D platform, which is anchored by the proprietary AI-driven Cloudscreen drug repurposing technology and spans oncology, autoimmune diseases, neurology, and obesity.<\/p>\n<p style=\"text-align: justify\">4,874,126 Series B Warrants have expired unexercised, eliminating approximately 38% of total outstanding warrants with no shareholder dilution. This represents a meaningful simplification of the <strong>COSM<\/strong> capital structure that directly benefits existing shareholders.<\/p>\n<p style=\"text-align: justify\"><img decoding=\"async\" src=\"https:\/\/www.globalnewslines.com\/uploads\/2026\/06\/59603fe13c53421c4d66b0b54a28b90a.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify\"><strong>COSM<\/strong> holds Real Estate Assets wholly owned, independently valued at over $15 Million. A large portion of these assets are free of any mortgage or other financial encumbrance. The market value of these assets alone exceed the Company&#8217;s current market capitalization and represent a meaningful component of the <strong>COSM<\/strong> asset base the Company believes is not yet reflected in its share price.<\/p>\n<p style=\"text-align: justify\"><strong>COSM<\/strong> has secured a financing facility of up to $300 million to support its digital assets treasury strategy. <strong>COSM<\/strong> has commenced investments in digital assets, with the strategy providing balance sheet diversification and a platform to explore blockchain&rsquo;s practical applications in healthcare, while retaining significant capital for core operations.<\/p>\n<p style=\"text-align: justify\"><strong>COSM<\/strong> is growing at its fastest pace in Company history &mdash; FY2025 revenue of $65.3 million was an all time annual record, up 20% year-over-year with gross profit growing 83%, followed by Q1 2026 revenue of $17.9 million, the highest in COSM history, up 31% year-over-year, with momentum continuing into Q2 2026 across all core divisions.<\/p>\n<p style=\"text-align: justify\"><strong>COSM<\/strong> 2026-2029 Guidance projects this trajectory to drive a structural transformation of the balance sheet: revenue growing to $200.6 million by 2029 at a 32% CAGR, gross margins expanding from 12.1% to 35.5%, Adjusted EBITDA reaching $44.2 million, operating cash flow of $24 million, a cash position of $62.9 million, and stockholders&#8217; equity growing 402% to $92.3 million &mdash; with all convertible debt projected to be fully repaid and cash expected to exceed total debt by 2027.<\/p>\n<p style=\"text-align: justify\"><strong>Entering $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657<\/strong><\/p>\n<p style=\"text-align: justify\">On June 1st <strong>COSM<\/strong> announced the extension of its C-Scrub antimicrobial wash brand into the veterinary and animal health sector through the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the Company&rsquo;s first entry into the animal health market.<\/p>\n<p style=\"text-align: justify\"><strong>COSM<\/strong> intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion to follow.<\/p>\n<p style=\"text-align: justify\">The global animal health market was estimated at approximately $68.7 billion in 2025 and is projected to reach $156.0 billion by 2033, growing at a compound annual growth rate of 11.0%, according to Grand View Research.<\/p>\n<p style=\"text-align: justify\"><img decoding=\"async\" src=\"https:\/\/www.globalnewslines.com\/uploads\/2026\/06\/5a15ceb0f0339e427f50c990fd5fe762.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify\">European Veterinary Standards Testing<\/p>\n<p style=\"text-align: justify\"><strong>COSM<\/strong> C-Scrub Wash 4% successfully demonstrated bactericidal activity according to EN 1656:2019 and yeasticidal activity according to EN 1657:2024 following independent testing conducted by Quality Assurance &amp; Control Systems Ltd. (QACS), an EU-based testing laboratory accredited according to EN ISO\/IEC 17025:2017.<\/p>\n<p style=\"text-align: justify\"><strong>For more information on $COSM visit: <\/strong><a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=R7nXxFXilYbwtJKzJ7v8JlPeraH-gaJ667Ij-4vXo5wuobDTPCGAmq03tOhutRepWP_9wzcEtvNckyUZnD0eWsKTQCkWaSOyRZKxT1mT1opj_4m_F0GI-j7C09j-_juc\" target=\"_blank\">www.cosmoshealthinc.com<\/a>, <a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=inyDqSBwih2Ca0UHcb4pxXUp-11gjhRkxXfd2IsUg4DtGUl8Hqsx2QOYi6EMuexKLQXWaZBOh2dIiXBzBa-lDkRwJM6GuNDCqWlQME5tzyE=\" target=\"_blank\">www.skypremiumlife.com<\/a>, <a rel=\"nofollow\" href=\"http:\/\/www.cana.gr\/en\/home\/\">www.cana.gr\/en\/home\/<\/a>, www.zipdoctor.co, https:\/\/cloudscreen.gr\/en\/<\/p>\n<p style=\"text-align: justify\"><strong>Email:<\/strong> cosm@bdgcommunications.com or info@cosmoshold.com<\/p>\n<p style=\"text-align: justify\">DISCLAIMER: <a rel=\"nofollow\" href=\"https:\/\/corporateads.com\/disclaimer\/\">https:\/\/corporateads.com\/disclaimer\/<\/a><\/p>\n<p style=\"text-align: justify\"><em>Disclosure listed on the CorporateAds website<\/em><\/p>\n<p class=\"caps\"><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong>  Cosmos Health, Inc. (Nasdaq: COSM)<br \/><strong>Contact Person:<\/strong> BDG Communications<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href='http:\/\/www.universalpressrelease.com\/?pr=653-million-revenue-in-2025-followed-by-q1-2026-record-of-179-million-with-momentum-continuing-in-q2-for-diversified-global-heath-leader-cosmos-health-inc-nasdaq-cosm'>Send Email<\/a><br \/><strong>Phone:<\/strong> (312) 865-0026<br \/><strong>Address:<\/strong>141 West Jackson Blvd., Suite 4234  <br \/><strong>City:<\/strong> Chicago<br \/><strong>State:<\/strong> IL 60604<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.cosmoshealthinc.com\/\" target=\"_blank\">https:\/\/www.cosmoshealthinc.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.getnews.info\/press_stat.php?pr=653-million-revenue-in-2025-followed-by-q1-2026-record-of-179-million-with-momentum-continuing-in-q2-for-diversified-global-heath-leader-cosmos-health-inc-nasdaq-cosm\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Guidance Targeting $200M Revenue, Adjusted EBITDA to $44.2 Million and Stockholders&#8217; Equity Growing 402% to $92.3 Million Portfolio of Proprietary Pharmaceutical and Nutraceutical Brands, Including Sky Premium Life&reg;, Mediterranation&reg;, bio-bebe&reg;,<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/597626"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=597626"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/597626\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=597626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=597626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=597626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}